血管内治疗复发颅内动脉瘤的显微外科管理:60例连续病例系列
该研究纳入2012至2022年间在作者机构收治的3128例颅内动脉瘤患者中60例(6.3%)血管内治疗后复发并接受显微外科治疗的连续病例,评估手术相关并发症。未破裂复发动脉瘤患者手术相关总并发症率为14.5%(8/55),其中3例(5.5%)出现与手术直接相关的术后缺血性并发症且均记录到术中破裂;54例存活未破裂患者中49例(91%)功能预后良好。作者认为显微外科仍是复发颅内动脉瘤的有效治疗选择,但术后并发症率高于非复发动脉瘤患者。
要点
- 未破裂复发动脉瘤显微手术后总并发症率14.5%(8/55),术后缺血性并发症3例(5.5%)。
- 54例存活未破裂患者中49例(91%)改良Rankin量表评分<3,功能预后良好。
- 功能预后不良与术中破裂显著相关;3例死亡(6%)死于动脉瘤破裂和/或重症监护并发症。
核心结论
- 显微外科仍是复发颅内动脉瘤的有效治疗选择,但作者经验中术后并发症率高于非复发动脉瘤患者。
- 作者认为治疗前多学科评估是必要的,以尽可能降低再治疗相关潜在并发症。
- 作者指出当血管内闭塞动脉瘤需要同时支架置入和弹簧圈栓塞时,应仔细评估替代显微外科治疗,因为动脉瘤复发时显微外科夹闭将变得更具挑战性。
研究设计与样本
- 回顾性系列:2012至2022年作者机构共管理3128例破裂或未破裂颅内动脉瘤患者,其中954例接受显微外科手术。
- 纳入60例(6.3%)既往血管内治疗后显微外科治疗复发的连续患者;进行术中及术后并发症记录、早期(<7天)和长期临床与影像学监测。
- 功能预后良好定义为改良Rankin量表评分<3。
主要发现
- 初次治疗时平均年龄45岁(范围26-65岁);首次治疗与复发显微外科治疗之间平均间隔64个月(范围2天-296个月)。
- 复发瘤底平均大小5 mm,复发瘤颈平均大小4.6 mm;5例(8.3%)表现为与复发动脉瘤破裂相关的蛛网膜下腔出血。
- 3例(6%)死于动脉瘤破裂和/或重症监护并发症。
- 未破裂复发动脉瘤患者显微外科手术相关总并发症率为14.5%(8/55);其中与显微外科手术直接相关的术后确定性并发症(缺血性病变)3例(5.5%),这3例均记录到术中破裂。
- 54例存活的未破裂复发动脉瘤患者中49例(91%)功能预后良好;功能预后不良与术中破裂显著相关。
临床怎么用
- 作者认为治疗前多学科评估是必要的,以尽可能降低再治疗相关潜在并发症。
- 作者指出当血管内闭塞动脉瘤需要同时支架置入和弹簧圈栓塞时,应仔细评估替代显微外科治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the morbidity associated with microsurgical treatment in patients with a recurrent aneurysm to improve their surgical management. METHODS: From 2012 to 2022, among the 3128 patients with ruptured or unruptured intracranial aneurysms managed at the authors' institution, 954 patients were treated by a microsurgical procedure. Of these 3128 patients, 60 consecutive patients (6.3%) who had a recurrent microsurgically treated aneurysm after previous endovascular treatment were included in this study. Additional microsurgical treatment was considered in case of progressive remnant growth or significant aneurysm recurrence. Intraoperative and postoperative complications were noted. Early (< 7 days) and long-term clinical and radiological monitoring were performed. Good functional outcome was considered as a modified Rankin Scale score < 3. RESULTS: The mean age at initial treatment was 45 years (range 26-65 years). The mean delay between the first treatment and microsurgical treatment of the recurrence was 64 months (range 2 days-296 months). The mean size of the fundus recurrence was 5 mm, and the mean size of the neck recurrence was 4.6 mm. Five patients (8.3%) presented with subarachnoid hemorrhage associated with rupture of the recurrent aneurysm. Three patients died (6%) of aneurysm rupture and/or intensive care complications. The total morbidity rate associated with the microsurgical procedure was 14.5% (8/55) in patients with unruptured recurrent aneurysms. Among these patients, postoperative definitive complications (ischemic lesions) directly related to the microsurgical procedure were present in 3 patients (5.5%). Intraoperative rupture was recorded in these 3 patients. In the 54 surviving patients with unruptured recurrent aneurysms, good functional outcome was noted in 49 (91%). Poor functional outcome was significantly associated with intraoperative rupture. CONCLUSIONS: Microsurgery remains an effective therapeutic option for recurrent intracranial aneurysms. However, in the authors' experience, postoperative morbidity is higher than in patients with nonrecurrent aneurysms. Therefore, a pretherapeutic multidisciplinary evaluation is mandatory to reduce the potential morbidity associated with the retreatment as much as possible. When endovascular occlusion of the aneurysm requires both stenting and coiling, alternative microsurgical treatment should be carefully evaluated, as microsurgical clipping will become much more challenging in cases of aneurysm recurrence.
引用
- Lejeune JP, Karnoub MA, Devalckeneer A, et al. Microsurgical management of recurrent intracranial aneurysm after endovascular treatment: a series of 60 consecutive patients. J Neurosurg. 2024. PMID: 38941640. doi:10.3171/2024.3.JNS24116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。